CCI-779 Inhibits Rhabdomyosarcoma Xenograft Growth by an Antiangiogenic Mechanism Linked to the Targeting of mTOR/Hif-1α/VEGF Signaling
Authors:
- Xiaolin WanXWXiaolin Wan
- Na ShenNSNa Shen
- Arnulfo MendozaAMArnulfo Mendoza
- Chand KhannaCKChand Khanna
- Lee J. HelmanLHLee J. Helman
Open Access
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Rapamycin Inhibits Ezrin-Mediated Metastatic Behavior in a Murine Model of OsteosarcomaCancer Research, 2005
- Targeting HIF-1 for cancer therapyNature Reviews Cancer, 2003
- Levels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-II-overexpressing rhabdomyosarcomas cellsOncogene, 2003
- Rheb promotes cell growth as a component of the insulin/TOR signalling networkNature Cell Biology, 2003
- Rheb is an essential regulator of S6K in controlling cell growth in DrosophilaNature Cell Biology, 2003
- Role of angiogenesis in tumor growth and metastasisSeminars in Oncology, 2002
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002
- Pediatric genitourinary tumorsCurrent Opinion in Oncology, 2002
- The rapamycin-sensitive signal transduction pathway as a target for cancer therapyOncogene, 2000
- Rapamycin: A novel immunosuppressive macrolideMedicinal Research Reviews, 1994